|
Market Cap (1-Jul) $6,688,688 (1,207th) |
Close (30-Jun) $0.200 |
Volume (30-Jun) 1,808,064 |
Shortsold (12-Jun) 8,499 (0.01%) (521st) |
|
52w High $0.100 |
52w Low $0.059 |
P/E - |
EPS 0 |
IXC released this announcement to the ASX on 24 October 2022, 9:21. The announcement is marked as price sensitive, and is 3 page(s) in length and 195.69kb in size.
You can view all announcements from IXC and see how they appear on a price chart on the announcements page.
At the date of this announcement, IXC was 0.023% short sold according to ASIC data. It was ranked the 554th most shorted stock on the ASX. It is now ranked as the 521st most shorted stock on the ASX with 0.011% of total shares short sold as of the latest reported data (12 June 2025).
| Other Recent Announcements from IXC | |
|---|---|
| Phase III Clinical Trial Update and New IIH Market Analysis | 28 June 2023, 8:40 |
| Invex Granted European Orphan Drug Designation for TBI | 23 June 2023, 8:18 |
| Invex Receives Regulatory Approval for IIH EVOLVE in France | 21 April 2023, 8:17 |
| First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial | 24 October 2022, 9:21 |
| First Australian Site Activated in IIH EVOLVE Phase 3 | 24 October 2022, 8:17 |
| Notice of Annual General Meeting/Proxy Form | 21 October 2022, 12:28 |
| Second HREC Approval for IIH EVOLVE Phase III Clinical Trial | 30 September 2022, 8:51 |
You must be logged in to post a reply.
Invex Therapeutics Ltd 